Coya Therapeutics, Inc. (COYA)
After hours:
| Previous close | 8.50 |
| Open | 8.50 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 8.34 - 8.79 |
| 52-week range | 3.21 - 10.69 |
| Volume | |
| Avg. volume | 90,200 |
| Market cap | 127.617M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
HOUSTON, May 09, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
- Business Wire
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
HOUSTON, April 26, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist Hospital (HMH), will present biomarker data today as part of a presentation at the 2nd Annual Johnson Center Symposium
- Business Wire
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
HOUSTON, April 22, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit being held May 20 – 21 at the Boston Harbor Hotel. Drs. Berman and Swaminathan will also be
